Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

9.61
+1.2514.95%
Post-market: 9.45-0.1600-1.66%17:59 EDT
Volume:1.91M
Turnover:17.92M
Market Cap:482.04M
PE:-3.10
High:9.78
Open:8.42
Low:8.32
Close:8.36
Loading ...

Regenxbio Q4 License & Royalty Revenue USD 21.214 Million

Reuters
·
14 Mar

Regenxbio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Mar

Regenxbio: Q4 Earnings Snapshot

Associated Press Finance
·
14 Mar

Regenxbio Q4 2024 GAAP EPS $(1.01) Beats $(1.15) Estimate, Sales $21.21M Miss $23.75M Estimate

Benzinga
·
14 Mar

Regenxbio Q4 Net Income USD -51.186 Million

THOMSON REUTERS
·
14 Mar

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

PR Newswire
·
14 Mar

Regenxbio Inc expected to post a loss of $1.15 a share - Earnings Preview

Reuters
·
12 Mar

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

PR Newswire
·
10 Mar

Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know

Zacks
·
06 Mar

Jim Cramer on REGENXBIO Inc. (RGNX): ‘This Thing Just Does Nothing But Go Down’

Insider Monkey
·
06 Mar

BRIEF-Regenxbio Announces Closing Of Strategic Partnership With Nippon Shinyaku For MPS Diseases

Reuters
·
04 Mar

Regenxbio Closes Partnership With Nippon Shinyaku

MT Newswires Live
·
04 Mar

Regenxbio closes strategic partnership with Nippon Shinyaku

TIPRANKS
·
04 Mar

Regenxbio Announces Closing of Strategic Partnership With Nippon Shinyaku for Mps Diseases

THOMSON REUTERS
·
04 Mar

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

PR Newswire
·
04 Mar

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

PR Newswire
·
27 Feb

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire
·
26 Feb

Leerink Partners Sticks to Their Buy Rating for RegenXBio (RGNX)

TIPRANKS
·
23 Feb

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Benzinga
·
12 Feb

Regenxbio Shares Fall After Downgrade From Goldman Sachs

MT Newswires Live
·
12 Feb